Quotient Technology

Quotient Therapeutics is a biotechnology company founded by Flagship Pioneering that leverages a proprietary somatic genomics platform to discover and develop transformative medicines. The company's platform systematically studies the genetic variation and evolution of the trillions of cells within the human body to identify novel links between genes and disease. By uncovering mutations that either drive disease or provide protection against it, Quotient aims to develop first-in-class therapies across a broad range of therapeutic areas, including immunology, cardiometabolic, and respiratory diseases. Since its unveiling in 2023, the company has secured major strategic partnerships with Pfizer, GSK, and Merck to identify and validate novel drug targets using its proprietary technology.